Caricamento...
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
BACKGROUND: The objective of this clinical open-label trial was to test the safety, tolerability and efficacy of IGF-1 therapy for autosomal dominant cerebellar ataxia (ADCA) patients. RESULTS: A total of 19 molecularly confirmed patients with SCA3, 1 patient with SCA6 and 6 patients with SCA7 compl...
Salvato in:
| Pubblicato in: | Cerebellum Ataxias |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4552149/ https://ncbi.nlm.nih.gov/pubmed/26331037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40673-014-0013-8 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|